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CONTROVERSY PERSISTS ON THEindications for screening andthreshold levels of thyroid-stimulating hormone (TSH)
for treatment of subclinical hypothyroid-
ism,1-3 defined as elevated serum TSH
levels with normal thyroxine (T4) con-
centrations. Because subclinical hypo-
thyroidism has been associated with hy-
percholesterolemia4 and atherosclerosis,5
screening and treatment have been ad-
vocated to prevent cardiovascular dis-
ease.3 However, data on the associa-
tions with coronary heart disease (CHD)
events and mortality are conflicting
among several large prospective co-
horts.6-9 Three recent study-level meta-
analyses10-12 found modestly increased
risks for CHD and mortality, but with
heterogeneity among individual stud-
ies that used different TSH cutoffs, dif-
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Context Data regarding the association between subclinical hypothyroidism and car-
diovascular disease outcomes are conflicting among large prospective cohort studies.
This might reflect differences in participants’ age, sex, thyroid-stimulating hormone
(TSH) levels, or preexisting cardiovascular disease.
Objective To assess the risks of coronary heart disease (CHD) and total mortality
for adults with subclinical hypothyroidism.
Data Sources and Study Selection The databases of MEDLINE and EMBASE (1950
to May 31, 2010) were searched without language restrictions for prospective cohort
studies with baseline thyroid function and subsequent CHD events, CHD mortality,
and total mortality. The reference lists of retrieved articles also were searched.
Data Extraction Individual data on 55 287 participants with 542 494 person-years
of follow-up between 1972 and 2007 were supplied from 11 prospective cohorts in
the United States, Europe, Australia, Brazil, and Japan. The risk of CHD events was
examined in 25 977 participants from 7 cohorts with available data. Euthyroidism was
defined as a TSH level of 0.50 to 4.49 mIU/L. Subclinical hypothyroidism was defined
as a TSH level of 4.5 to 19.9 mIU/L with normal thyroxine concentrations.
Results Among 55 287 adults, 3450 had subclinical hypothyroidism (6.2%) and 51 837
had euthyroidism. During follow-up, 9664 participants died (2168 of CHD), and 4470
participants had CHD events (among 7 studies). The risk of CHD events and CHD mor-
tality increased with higher TSH concentrations. In age- and sex-adjusted analyses,
the hazard ratio (HR) for CHD events was 1.00 (95% confidence interval [CI], 0.86-
1.18) for a TSH level of 4.5 to 6.9 mIU/L (20.3 vs 20.3/1000 person-years for par-
ticipants with euthyroidism), 1.17 (95% CI, 0.96-1.43) for a TSH level of 7.0 to 9.9
mIU/L (23.8/1000 person-years), and 1.89 (95% CI, 1.28-2.80) for a TSH level of 10
to 19.9 mIU/L (n=70 events/235; 38.4/1000 person-years; P.001 for trend). The
corresponding HRs for CHD mortality were 1.09 (95% CI, 0.91-1.30; 5.3 vs 4.9/
1000 person-years for participants with euthyroidism), 1.42 (95% CI, 1.03-1.95; 6.9/
1000 person-years), and 1.58 (95% CI, 1.10-2.27, n=28 deaths/333; 7.7/1000 person-
years; P=.005 for trend). Total mortality was not increased among participants with
subclinical hypothyroidism. Results were similar after further adjustment for tradi-
tional cardiovascular risk factors. Risks did not significantly differ by age, sex, or pre-
existing cardiovascular disease.
Conclusions Subclinical hypothyroidism is associated with an increased risk of CHD
events and CHD mortality in those with higher TSH levels, particularly in those with a
TSH concentration of 10 mIU/L or greater.
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ferent confounding factors for adjust-
ment, and varying CHD definitions.10
Part of the heterogeneity might also be
related to differences in participants’ age,
sex, or severity of subclinical hypothy-
roidism (as measured by TSH level).4
One cohort study suggested particu-
larly high risk in participants with sub-
clinical hypothyroidism and preexist-
ing cardiovascular disease.8
Analysis of individual participant
data from large cohort studies may rec-
oncile these conflicting data and de-
fine the influence of age, TSH levels, and
preexisting cardiovascular disease. In-
dividual participant data analysis is con-
sidered the best way for synthesizing
evidence across several studies be-
cause it is not subject to potential bias
from study-level meta-analyses (eco-
logical fallacy)13 and allows perfor-
mance of time-to-event analyses.14
To clarify the cardiovascular risk of
subclinical hypothyroidism, we formed
the Thyroid Studies Collaboration and
conducted an individual participant
data analysis of subclinical hypothy-
roidism and CHD outcomes.
METHODS
Identification of potential studies was
based on protocols developed for our
study-level meta-analysis of prospec-
tive cohort studies.10 Briefly, we con-
ducted a systematic literature search of
articles in all languages on the associa-
tion between subclinical thyroid dys-
function and CHD or mortality (car-
diovascular and total) published from
1950 to May 31, 2010, in the MEDLINE
and EMBASE databases and searched
bibliographies of key articles (details are
available in the eMethods at http://www
.jama.com). To maximize the quality
and comparability of the studies, we for-
mulated general inclusion criteria a
priori. We included only full-text, pub-
lished longitudinal cohort studies that
(1) measured thyroid function with
both serum TSH level and thyroxine
(T4) level at baseline in adults, (2) fol-
lowed up participants systematically
over time, (3) assessed CHD events
and/or mortality, and (4) had a com-
parison group with euthyroidism. We
excluded studies that only examined
persons taking antithyroid medica-
tions, thyroxine replacement or amio-
darone, or with overt hypothyroidism
(defined as low T4 and elevated TSH
concentrations). Possible studies for in-
clusion were independently assessed for
suitability by 2 of the authors (N.R.,
J.G.) and any disagreement was re-
solved by discussion with a third au-
thor (D.C.B). The agreement between
the 2 reviewers was 99.9% for the first
screen (titles and abstracts, =0.98) and
100% for the full-text screen (=1.00).
Investigators fromeacheligible study
were invited to join the Thyroid Stud-
ies Collaboration.Wecollecteddetailed
informationaboutprespecifiedoutcomes
and potential confounding variables for
each participant. Requested data in-
cluded individual demographic charac-
teristics,baseline thyroid function(TSH
and T4 levels), baseline cardiovascular
risk factors (eg, low- and high-density
lipoprotein cholesterol level, diabetes,
blood pressure, cigarette smoking),
prevalent cardiovascular disease, medi-
cation use at baseline (thyroid medica-
tion, lipid-lowering and antihyperten-





Cardiovascular Health Study,6,15 we de-
finedsubclinicalhypothyroidismasase-
rum TSH level of 4.5 mIU/L or greater to
lessthan20mIU/L,withanormalT4 con-
centration;andeuthyroidismwasdefined
as a serum TSH level of 0.5 mIU/L or
greater and less than4.5mIU/L.Because
the Whickham Survey used a first-
generation TSH radioimmunoassay,
which gives higher measured TSH val-
ues thancurrent assays,16 aTSHrangeof
6.0 mIU/L or greater to less than 21.5
mIU/L was used for this individual par-
ticipant data analyses, as in the original




ies,18 which is close to the modern level
of 4.5 mIU/L for the current generation
of assays. For T4 level, we used site- and
method-dependent specific cutoffs
(eTable at http://www.jama.com) be-
cause T4 measurements show greater in-
termethod variation than do sensitive
TSH assays. The Whickham Survey mea-
sured total T4 level.18 Participants with
abnormal T4 values, results suggestive
of nonthyroidal illness (low TSH and FT4
levels) or low TSH level (0.5 mIU/L)
were excluded (n=3023). Some stud-
ies had participants with missing T4 val-
ues (eTable); we considered partici-
pants with a TSH level of 4.5 mIU/L to
19.9 mIU/L and a missing T4 level as hav-
ing subclinical hypothyroidism be-
cause most adults with this degree of
TSH elevation have subclinical and not
overt hypothyroidism.19 We per-
formed a sensitivity analysis excluding
those with a missing T4 level.
Outcome measures were CHD
events, CHD mortality, and total mor-
tality. To limit outcome heterogeneity
observed with previous study-level
meta-analyses,10-12 we used more ho-
mogeneous outcome definitions. Simi-
lar to the current Framingham risk
score,20 we limited cardiovascular mor-
tality to CHD mortality or sudden death
(eTable). A CHD event was defined as
nonfatal myocardial infarction or CHD
death (equivalent to hard events in the
Framingham risk score20) and hospi-
talization for angina or coronary revas-
cularization (coronary artery bypass
grafting or angioplasty).6 We per-
formed a sensitivity analysis with hard
events only.
Using previously described criteria10
and new information from study au-
thors, we systematically evaluated the fol-
lowing key indicators of study qual-
ity13: methods of outcome adjudication
and ascertainment, accounting for con-
founders, and completeness of fol-
low-up ascertainment. Two reviewers
(N.R., J.G.) rated all studies for quality.
We used separate Cox proportional
hazard models to assess the associa-
tions of subclinical hypothyroidism with
CHD events and mortality for each co-
hort (SAS version 9.2, SAS Institute Inc,
Cary, North Carolina). Pooled esti-
mates for each outcome were calcu-
lated using random-effects models, based
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on the variance model according to
DerSimonian and Laird,21 as recom-
mended14,22 and published in recent
2-stage individual participant data analy-
ses.23 Results were summarized using for-
estplots (ReviewManagerversion5.0.24,
Nordic Cochrane Centre, Copenhagen,
Denmark). The research authors of
1 study with 14 CHD outcomes5,10
declined to participate; as recom-
mended,24 we included the published
summary estimate from that study in the
random-effects models in a sensitivity
analysis. To assess heterogeneity across
studies, we used the I2 statistic, which de-
scribes the total variation across studies
attributable to heterogeneity rather than
chance (I250% indicating at least mod-
erate statistical heterogeneity).25
Primary analyses were adjusted for
age and sex, and then for traditional car-
diovascular risk factors (systolic blood
pressure, smoking, total cholesterol,
diabetes) that were available in all co-
horts (except for the Birmingham
Study,26 which was excluded from this
analysis). We considered the age- and
sex-adjusted model as the primary
analysis because some traditional risk
factors are potential mediators of the re-
lationship between subclinical hypo-
thyroidism and CHD.4
To explore sources of heterogeneity,
we performed several predefined sub-
group and sensitivity analyses. We con-
ductedstratifiedanalysesbyage,sex,race,
TSHconcentrations, andpreexistingcar-
diovascular disease. Based on expert
reviews1,2 and previous studies,7,15 sub-
clinical hypothyroidism was stratified
according to the following TSH concen-
tration categories: 4.5-6.9 mIU/L (mild
elevation), 7.0-9.9 mIU/L (moderate
elevation),and10.0-19.9mIU/L(marked
elevation). In the study-specific analy-
ses stratified by age or TSH level, some
strata had participants without either
CHD deaths or CHD events (for 1
study27). For these study-specific analy-
ses, we used penalized likelihood meth-
ods28 to obtain hazard ratios (HRs) and
confidence intervals (CIs). As done in
previous studies,7,27,29 after including all
participants in the primary analyses, we
performed sensitivity analyses exclud-
ing participants who had thyroid hor-
mone use at baseline and during follow-
up. To calculate age- and sex-adjusted
rates per 1000 person-years, we first fit
Poissonmodels30 to thepooleddata, then
standardized the fitted rate in the euthy-
roidism group to the overall age and sex
distributionofthepooledsample.Finally,
to obtain rates in the TSH groups con-
sistent with the meta-analytic results, we
multiplied the standardized rates in the
euthyroidism group by the summary
meta-analytic HRs. We checked the pro-
portional hazard assumption using
graphical methods and Schoenfeld tests
(allP.05).WeusedtheEgger test31 and
age- and sex-adjusted funnel plots to
assess for publication bias.
RESULTS
Among 4440 reports identified, 12 pro-
spective studies met eligibility criteria
(eFigure at http://www.jama.com) and
11 prospective cohorts in the United
States, Europe, Australia, Brazil, and Ja-
pan agreed to provide individual partici-
pant data (TABLE 1). The final sample in-
cluded 55 287 adults comprising 3450
with subclinical hypothyroidism (6.2%)
and 51 837 with euthyroidism. Zero to
8.3% of participants reported thyroid
hormone use at baseline (all excluded in
5 studies) and 0% to 12.6% reported thy-
roid hormone use during follow-up. The
median follow-up ranged from 2.5 to 20
years, with total follow-up of 542 494
person-years.
All 11 cohort studies reported total
and CHD deaths, and 7 studies also re-
ported CHD events among 25 977 par-
ticipants. For the quality of individual
studies, all studies reported outcome ad-
judication without knowledge of thy-
roid status; 4 of 7 studies reporting CHD
events used formal adjudication pro-
cedures6-8,27; and 4 of 11 studies report-
ing CHD deaths mainly used death cer-
tificates.26,33-35 All studies had 5% or less
loss to follow-up.
During follow-up, 9664 participants
died (2168 of CHD) and 4470 partici-
pants had CHD events (among 7 stud-
ies). In age- and sex-adjusted analyses,
the overall HR for participants with sub-
clinical hypothyroidism compared with
euthyroidism was 1.18 (95% CI, 0.99-
1.42) for CHD events (24.0 vs 20.3/
1000 person-years for participants with
euthyroidism), 1.14 (95% CI, 0.99-
1.32) for CHD mortality (5.5 vs 4.9/
1000 person-years), and 1.09 (95% CI,
0.96-1.24) for total mortality (23.1 vs
21.1/1000 person-years; FIGURE 1). We
found heterogeneity across studies for
CHD events (I2=59%) and total mor-
tality (I2=66%), but not for CHD mor-
tality (I2=0%). We subsequently exam-
ined whether heterogeneity was related
to differences in risks by degree of sub-
clinical hypothyroidism and age. The
risk of CHD events (P.001 for trend)
and CHD death (P=.005 for trend) in-
creased with higher TSH level, but not
for total mortality (FIGURE 2). In strati-
fied analyses, participants with TSH lev-
els of 10 mIU/L or greater had signifi-
cantly increased risk of CHD events
(HR, 1.89 [95% CI, 1.28-2.80]; n=70
events/235; 38.4 vs 20.3/1000 person-
years for participants with euthyroid-
ism) and CHD mortality (HR, 1.58
[95% CI, 1.10-2.27]; n = 28 deaths/
333; 7.7 vs 4.9/1000 person-years) com-
pared with participants with euthyroid-
ism. The risk for CHD associated with
subclinical hypothyroidism appeared to
be somewhat higher in younger par-
ticipants, but the number of outcomes
in the younger age group was small, and
there was no significant trend in CHD
risk across age groups. Otherwise, the
risk estimates for CHD events, CHD
mortality, and total mortality did not
differ significantly according to age, sex,
race, or preexisting cardiovascular dis-
ease, except an increase in CHD events
and CHD mortality among white but
not among nonwhite participants with
subclinical hypothyroidism (TABLE 2).
All results were similar after further ad-
justment for traditional cardiovascu-
lar risk factors.
Sensitivity analyses yielded similar re-
sults, with increased risks of CHD
events and mortality in those with TSH
levels of 10 mIU/L or greater (TABLE 3).
Risk estimates were slightly higher for
those with TSH levels of 10 mIU/L or
greater after excluding those who took
thyroid medication during follow-up.
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Estimates were lower for subclinical hy-
pothyroidism overall after limiting the
analyses to 4 studies with formal adju-
dication procedures, but slightly higher
for those with TSH levels of 10 mIU/L
or greater. The effect of increasing TSH
level on CHD events did not signifi-
cantly differ according to age (P=.87 for
interaction). We found no evidence of
publication bias, either with visual as-
sessment of age- and sex-adjusted fun-
nel plots or with the Egger test for mor-
tality data (P=.39 for CHD mortality
and P=.97 for total mortality) and little
evidence of publication bias for CHD
events (P=.13 for CHD events).
COMMENT
In this analysis of 55 287 individual par-
ticipants from 11 prospective cohort
studies, subclinical hypothyroidism was
associated with an increased risk of
CHD events and CHD mortality in
those with higher TSH levels. There was
a significant trend of increased risk at
higher serum TSH concentrations, and
the risk of both CHD mortality and
CHD events was significantly in-
creased in participants with TSH lev-
els of 10 mIU/L or greater. These asso-
ciations persisted after adjustment for
traditional cardiovascular risk factors,
and did not significantly differ by age,
sex, race, or preexisting cardiovascu-
lar disease. Compared with partici-
pants with euthyroidism, the overall HR
for CHD events with subclinical hypo-
thyroidism was 1.18 (95% CI, 0.99-
1.42) and the overall HR for CHD mor-
tality was 1.14 (95% CI, 0.99-1.32).
Minimal TSH elevations were not as-
sociated with an increased risk of CHD
events and CHD mortality. Our re-
sults clarify the CHD risk of sub-
groups of adults with subclinical hy-
pothyroidism, which could not be
adequately addressed in previous study-
level meta-analyses10-12 or in single co-
hort studies performed in more lim-
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518 (53.0) 101 (10.3) 0 NA 1999-2000 7.3
(7.0-7.5)
6875
Abbreviations: CDA, community-dwelling adult; IQR, interquartile range (25th-75th percentiles); NA, data not available.
aParticipants younger than 18 years were not included.
bFor all cohorts, the maximal follow-up data that were available were used, which might differ from previous reports for some cohorts.
cThe numbers of participants with thyroid medication use and thyroid-stimulating hormone levels of 10 mIU/L or greater were 12 of 222 in the Health, Aging, and Body Composition
Study; 3 of 14 in the Leiden 85-plus Study; 12 of 12 in the Pisa cohort; 2 of 99 in the Whickham Survey; 2 of 15 in the Busselton Health Study; and 2 of 33 in the Nagasaki Adult
Health Study.
dExcluded patients with acute coronary syndrome or severe illness.
SUBCLINICAL HYPOTHYROIDISM AND RISK OF CORONARY HEART DISEASE, MORTALITY
1368 JAMA, September 22/29, 2010—Vol 304, No. 12 (Reprinted) ©2010 American Medical Association. All rights reserved.
 at Leiden University Medical Center on May 3, 2012jama.ama-assn.orgDownloaded from 
ited age groups or without TSH
stratification.6,7,26,27
These results are generally consis-
tent with previous study-level meta-
analyses showing modest increased
risks of CHD events and cardiovascu-
lar mortality associated with subclini-
cal hypothyroidism.10,11 However, these
meta-analyses could not accurately ex-
plore potential differences related to
participant characteristics (eg, age, TSH
concentrations) because of potential
bias without individual participant data
analysis (ecological fallacy),13 and they
also were limited by clinical heteroge-
neity,10,36 with individual studies using
varying TSH cutoffs, confounding fac-
tors for adjustment, and CHD defini-
tions. Among 11 cohorts, only 2 stud-
ies previously reported results stratified
by TSH level. One study9 reported an
increased risk of CHD events in par-
ticipants with a TSH level of 10.0 mIU/L
or greater (HR, 2.2; 95% CI, 1.2-4.2)
and the other study7 reported an in-
creased risk of cardiovascular mortal-
ity (HR, 2.26; 95% CI, 0.54-9.45) but
not CHD events (HR, 0.96; 95% CI,
0.35-2.61) over 4 years among adults
aged 70 to 79 years with TSH levels of






















Cardiovascular Health Study,6 2006 180 492 955 2511 1.00 (0.85-1.17) 22.9
Health, Aging, and Body Composition Study,7 2005 62 335 493 2325 0.89 (0.68-1.16) 17.4
EPIC-Norfolk Study,32 2010 103 720 1575 11 897 1.09 (0.89-1.33) 20.8
Leiden 85-plus Study,27 2004 7 35 76 449 1.29 (0.59-2.80) 4.5
Pisa cohort,8 2007 20 228 148 2647 1.72 (1.07-2.74) 9.7
Whickham Survey,17,18 1996, 2010 27 121 438 2239 1.32 (0.89-1.96) 11.9
Busselton Health Study,9 2005 31 89 355 1889 1.78 (1.22-2.58) 12.8
Total (I2 = 59%) 430 2020 4040 23 957 1.18 (0.99-1.42) 100.0
0.2 0.5 1 2 5
HR (95% CI)
Total Mortality 
Cardiovascular Health Study,6 2006 310 492 1514 2511 1.07 (0.95-1.21) 13.8
Health, Aging, and Body Composition Study,7 2005 92 335 699 2325 0.89 (0.72-1.11) 11.0
Birmingham Study,26 2001 32 92 435 1006 0.92 (0.64-1.33) 7.1
EPIC-Norfolk Study,32 2010 108 720 1716 11 897 0.97 (0.80-1.18) 11.6
HUNT Study,33 2008 116 814 2159 23 776 0.99 (0.82-1.19) 11.9
Leiden 85-plus Study,27 2004 26 35 364 451 0.85 (0.57-1.27) 6.4
Pisa cohort,8 2007 39 228 238 2647 2.13 (1.52-3.00) 7.6
Whickham Survey,17,18 1996, 2010 49 124 681 2282 0.98 (0.73-1.31) 8.7
Busselton Health Study,9 2005 36 89 479 1895 1.44 (1.02-2.03) 7.6
Nagasaki Adult Health Study,34 2004 94 420 409 2171 1.04 (0.83-1.31) 10.8
Brazilian Thyroid Study,35 2010 13 101 55 876 1.96 (1.07-3.61) 3.6
Total (I2 = 66%) 915 3450 8749 51 837 1.09 (0.96-1.24) 100.0
0.2 0.5 1 2 5
HR (95% CI)
CHD Mortalityc 
Cardiovascular Health Study,6 2006 75 491 365 2511 1.09 (0.85-1.40) 33.8
Health, Aging, and Body Composition Study,7 2005 19 335 156 2325 0.85 (0.53-1.37) 9.2
Birmingham Study,26 2001 11 92 113 1006 1.21 (0.64-2.29) 5.2
EPIC-Norfolk Study,32 2010 31 720 422 11 897 1.19 (0.83-1.72) 15.6
HUNT Study,33 2008 24 814 375 23 776 1.09 (0.72-1.65) 12.1
Leiden 85-plus Study,27 2004 3 35 41 446 0.87 (0.27-2.82) 1.5
Pisa cohort,8 2007 14 228 92 2647 1.91 (1.08-3.36) 6.6
Whickham Survey,17,18 1996, 2010 16 124 223 2282 1.08 (0.64-1.81) 7.8
Busselton Health Study,9 2005 13 89 144 1892 1.67 (0.94-2.97) 6.3
Nagasaki Adult Health Study,34 2004 4 420 27 2171 0.67 (0.23-1.91) 1.9
Total (I2 = 0%) 210 3348 1958 50 953 1.14 (0.99-1.32) 100.0
aThe sizes of the data markers are proportional to the inverse variance of the hazard ratios (HRs). CI indicates confidence interval; HUNT, Nord-Trøndelag Health
Study; HR, hazard ratio.
bForty-six participants from the Whickham survey and 3 participants from the Busselton Health Study were not included because follow-up data were only available for death.
cNine participants were excluded from the analysis because of missing cause of death. The Brazilian Thyroid Study was not included in this analysis because of unreliable es-
timates based on the small number of CHD deaths (n=10).
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10 mIU/L or greater. However, the HR
for CHD events increased to 1.28 (95%
CI, 0.68-2.39) with extended follow-up
to 8 years in the present data. In overall
pooled data, we found statistical hetero-
geneity among individual study find-
ings for CHD events (I2=59%), but not
for CHD death. Part of the heterogeneity
might be related to different CHD risks
across age, race, and TSH subgroups.
Our individual participant data analy-
sis found that the CHD outcomes in
adults with subclinical hypothyroidism
did not differ significantly across age
groups. For the specific age group of 80
years or older, there was no significant
increased risk of total mortality, CHD
mortality, or CHD events in contrast to
a single previous study that found re-
duced mortality associated with increas-
ing TSH concentrations.27,37 Previous
study-level meta-analyses have found in-
creased risks of CHD events and cardio-
vascular mortality associated with sub-
clinical hypothyroidism, particularly in
studies with a mean age of younger than
65 years,10,11 but this was not confirmed
by our individual participant data analy-
sis. We found some evidence for in-
creased risks of CHD events and mor-
Figure 2. Hazard Ratios (HRs) for Coronary Heart Disease (CHD) Events, CHD Mortality, and Total Mortality According to Elevated






















P<.001 for trendCHD Mortality by



















































by Age, yb 
18-49 12 221 272 5405 1.46 (0.82-2.62)
50-64 54 517 997 7876 1.13 (0.73-1.77)
65-79 322 1158  2511 9668 1.20 (0.95-1.51)
≥80 42 124  260 1008 1.30 (0.93-1.82)
CHD Mortality,
by Age, yc 
18-49 2 444 54 13 560 2.13 (0.74-6.14)
50-64 16 1072 316 18 513 1.30 (0.81-2.08)
65-79 163 1608 1288 16 567 1.32 (1.08-1.62)
≥80 29 224 300 2313 1.01 (0.62-1.63)
Total Mortality,
by Age, yd 
18-49 14 465  340 13 832 1.31 (0.76-2.26)
50-64 108 1121 1492 18 875 1.17 (0.90-1.51)
65-79 623 1636 5316 16 785 1.17 (0.99-1.39)
≥80 170 228 1601 2345 0.96 (0.81-1.12)
P = .78 for trend
P = .22 for trend
P = .29 for trend
aThe sizes of the filled square data markers are proportional to the inverse variance of the HRs. The unfilled squares indicate the reference categories. For the analyses stratified
by age, the HRs for CHD events, CHD mortality, and total mortality were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata.
CI indicates confidence interval.
bData were available from 7 studies.
cData were available from 10 studies. The Brazilian Thyroid Study was not included because of unreliable estimates based on the small number of CHD deaths (n=10). Nine
participants were excluded from the analysis because of missing cause of death.
dData were available from 11 studies.
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tality in younger adults with subclinical
hypothyroidism,but therealsowere large
95% CIs without significant trend across
age groups (Figure 2). Moreover, the
effect of increasing TSH level on CHD
events did not significantly differ accord-
ing to age. In contrast to a previous study
suggesting that adults with subclinical
hypothyroidism and preexisting cardio-
vascular disease might be at particu-
larly high cardiovascular risk,8 we found
no significant effect of baseline preex-




might be related to the known effects of
thyroid hormone on the heart and
metabolism, consistent with the con-
cept that subclinical hypothyroidism is
a milder form of overt hypothyroid-
Table 2. Stratified Analyses for the Associations Between Subclinical Hypothyroidism and Risk of Coronary Heart Disease (CHD) Events, CHD
Mortality, and Total Mortality





















































































































P for trend .78 .58 .22 .12 .29 .15
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P for interaction .05 .05 .23 .18 .52 .51
TSH, mIU/L































































P for interaction .96 .57 .29 .35 .89 .57
Abbreviations: CI, confidence interval; HR, hazard ratio; NA, data not applicable; TSH, thyroid-stimulating hormone.
aData were available from 7 studies. Forty-six participants from the Whickham survey and 3 participants from the Busselton Health Study were not included in the analysis of CHD events
because follow-up data were only available for death.
bNine participants were excluded from this analysis because of missing cause of death. The Brazilian Thyroid Study was not included in this analysis because of unreliable estimates due
to the low number of CHD deaths (n=10).
cAdjusted for sex, age, systolic blood pressure, current and former smoking, total cholesterol, and prevalent diabetes at baseline. The Birmingham Study was not included in this analysis
because of lack of data on cardiovascular risk factors.
dThese HRs were not adjusted for sex.
eThese HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata.
fData were not available for the Birmingham study (n=1098).
gData were not available for the Birmingham study (n=1098). Thirty-seven participants with missing information on baseline cardiovascular disease from other studies were excluded from
this analysis. For analysis of CHD events, 286 participants without preexisting cardiovascular disease from the Leiden 85-plus Study were further excluded because of no CHD event.
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ism.38,39 Increasedsystemicvascularresis-
tance, arterial stiffness, altered endothe-
lial function, increased atherosclerosis,
and altered coagulability have been
reported to be associated with subclini-
cal hypothyroidism and may accelerate
development of CHD.4,39,40 The fact that
adjustment for traditional cardiovascu-
lar risk factors did not alter risks could
favor this hypothesis. Other potential
mechanisms include elevated choles-
terol level,4,39 although adjustment for
Table 3. Sensitivity Analysis of the Effect of Subclinical Hypothyroidism on the Risk of Coronary Heart Disease (CHD) Events and CHD Mortalitya
CHD Events by Thyroid-Stimulating
Hormone Level, mIU/Lb
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Rotterdam Study,5,k 4050/24 807 434/2127 1.20
(1.00-1.44)
NAl NAl NAl
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CI, confidence interval; HR, hazard ratio; NA, data not applicable.
aThe HRs were adjusted for age and sex using a random-effects model.
bData were available from 7 studies.
cThe numbers of participants with thyroid medication use appear in columns 7 and 8 of Table 1. The HUNT Study and the EPIC-Norfolk Study were not included in this analysis because
of lack of this information during follow-up.
dThe numbers of participants appear in the eTable at http://www.jama.com.
eDefined as hospitalization for angina or revascularization (coronary angioplasty or surgery) and participants with these outcomes were excluded from this analysis, which was possible
for participants from 4 studies (eTable). In contrast, hard events were defined as nonfatal myocardial infarction or CHD death, as defined in the current Framingham risk score.20
fDefined as having clear criteria for the outcomes that were reviewed by experts for each potential case (eg, specific electrocardiogram or cardiac enzymes modifications for CHD). For
this analysis, CHD adjudication based only on death certificates was not considered as a formal adjudication procedure.
gThe Birmingham Study was excluded from these analyses because of lack of data on cardiovascular risk factors. Data on lipid-lowering and antihypertensive medications were not
available for the EPIC-Norfolk and Nagasaki Adult Health studies.
hWith further adjustment for cardiovascular risk factors after excluding the Pisa cohort, the HRs for TSH level of 10-19.9 mIU/L were 1.63 (95% CI, 1.13-2.34) for CHD events, 1.52 (95%
CI, 1.04-2.23) for CHD mortality, and 1.05 (95% CI, 0.79-1.40) for total mortality (vs an HR of 1.06 [95% CI, 0.83-1.35] in age- and sex-adjusted analyses excluding the Pisa cohort).
iNo data on CHD events were available.
jHad the lowest rate of subclinical hypothyroidism (3.3%, Table 1).
kThis study had 14 CHD events5,10 but did not accept invitation to share individual participant data. Summary estimates of this study, adjusted for age, BMI, total cholesterol, high-density
lipoprotein cholesterol, blood pressure, and smoking were used in the random-effect models as a sensitivity analysis.24
lThe TSH subgroups were not reported in the study.
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cholesterol leveldidnot remove theasso-
ciations in our data. Adults with higher
TSH concentrations also are more likely
to develop overt hypothyroidism,41 and
it ispossiblethat thisprogressionexplains
the association with subclinical hypo-
thyroidism. Alternative explanations for
the observed results are bias in the selec-
tion of included studies, bias and qual-
ity problems in the original studies,
publication bias, and unmeasured con-
founders.42 Sensitivity analyses pooling
higher-quality studies yielded similar
results. Whereas one randomized con-
trolled trial has shown benefits with thy-
roxine treatment of subclinical hypothy-
roidismonintima-media thickness40 and
another has shown benefits with thyrox-
ine treatment of subclinical hypothy-
roidism on brachial artery endothelial
function,43 the potential causal relation-
ship can only be proven by randomized
controlled trials of thyroxine replace-
ment and clinical outcomes.36
Among the strengths of our study, an
individualparticipantdataanalysis is the
preferred way to perform time-to-event
analyses to avoid biases associated with
the use of aggregate data in meta-
regression for subgroup analysis and to
allow standardization of definitions of
predictors,outcomes,andadjustment for
potential confounders.14,22 We included
all available international and pub-
lisheddataon theseassociations.Among
the limitations of our study, the indi-
vidual participant data analysis included
predominantlywhitepopulations,except
for 2 studies conducted in Japan34 and
Brazil.35 Results for subgroups at risk of
CHD mortality generally had wider 95%
CIs than those for CHD events, reflect-
ing less statistical power. However, post
hoc calculations showed 80% power to
detect meaningful differences between
overall subclinical hypothyroidism and
euthyroidism groups for each outcome.
Specifically, our study had adequate
power to detect an HR of 1.18 or higher
for CHD events, an HR of 1.30 or higher
for CHD mortality, and an HR of 1.13 or
higher for total mortality. Even with this
very large amount of individual partici-
pantdata,ourpower for subgroupanaly-
ses was limited among those with TSH
levels of 10 mIU/L or greater or adults
younger than50yearsbecauseof the lim-
ited number of CHD events and deaths.
Thyroid function testing was per-
formed only at baseline, and we have no
data on how many participants pro-
gressed from euthyroidism to subclini-
cal hypothyroidism, from subclinical to
overt hypothyroidism, or who normal-
ized their TSH level over time, which is
a limitation of all published large
cohorts.6,7,33 In addition, free triiodothy-
ronine (T3) was not available in most
cohorts, and thus could not be included
in thyroid status classification. Com-
mencement of thyroid medication dur-
ing follow-up by up to 12.6% of partici-
pants might have attenuated any true
effects of subclinical hypothyroidism, as
illustrated by the sensitivity analysis
excluding such participants.
In summary, combining all available
data from large prospective cohorts
among 55 287 individual participants
suggests that subclinical hypothyroid-
ism is associated with an increased risk
of CHD in those with higher TSH levels.
TheriskofbothCHDmortalityandCHD
events, but not of total mortality,
increases with higher concentrations of
TSHandissignificantlyelevated inadults
with TSH levels of 10 mIU/L or greater.
Conversely, minimal TSH elevations are
not associated with an increased risk of
CHD events and CHD mortality. Our
finding of no increased risk of CHD
among the high proportions of adults
with minimal TSH elevations is also
important because many patients with
minimal TSH elevations are currently
treated in clinical practice.44 Our results
might help refine a TSH threshold at
which larger clinical benefits of thyrox-
ine replacement would be expected.4,45
Our study cannot address whether these
risks are attenuated or abolished by thy-
roxine replacement. Given the high
prevalence of subclinical hypothyroid-
ism,2,19 this question needs to be
addressed in an appropriately powered
randomized controlled trial.
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